WO2007073706A3 - Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas - Google Patents

Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas Download PDF

Info

Publication number
WO2007073706A3
WO2007073706A3 PCT/CU2006/000020 CU2006000020W WO2007073706A3 WO 2007073706 A3 WO2007073706 A3 WO 2007073706A3 CU 2006000020 W CU2006000020 W CU 2006000020W WO 2007073706 A3 WO2007073706 A3 WO 2007073706A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
peptides
repeating units
pharmaceutical industry
antigens
Prior art date
Application number
PCT/CU2006/000020
Other languages
English (en)
French (fr)
Other versions
WO2007073706A2 (es
Inventor
Medina Tamara Menendez
Leal Yoelys Cruz
Acosta Osvaldo Reyes
Perez Hilda Elisa Garay
Nieto Gerardo Enrique Guillen
Rodriguez Edelgis Coizeau
Vispo Nelson Francisc Santiago
Santiago Glay Chinea
Original Assignee
Ct Ingenieria Genetica Biotech
Medina Tamara Menendez
Leal Yoelys Cruz
Acosta Osvaldo Reyes
Perez Hilda Elisa Garay
Nieto Gerardo Enrique Guillen
Rodriguez Edelgis Coizeau
Vispo Nelson Francisc Santiago
Santiago Glay Chinea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Medina Tamara Menendez, Leal Yoelys Cruz, Acosta Osvaldo Reyes, Perez Hilda Elisa Garay, Nieto Gerardo Enrique Guillen, Rodriguez Edelgis Coizeau, Vispo Nelson Francisc Santiago, Santiago Glay Chinea filed Critical Ct Ingenieria Genetica Biotech
Priority to CA002634067A priority Critical patent/CA2634067A1/en
Priority to EP06828471A priority patent/EP1982994A2/en
Priority to MX2008008582A priority patent/MX2008008582A/es
Priority to BRPI0620937-8A priority patent/BRPI0620937A2/pt
Priority to AU2006331226A priority patent/AU2006331226A1/en
Publication of WO2007073706A2 publication Critical patent/WO2007073706A2/es
Publication of WO2007073706A3 publication Critical patent/WO2007073706A3/es
Priority to NO20083301A priority patent/NO20083301L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención esta relacionada con la industria farmacéutica y la biotecnología, mas específicamente con antígenos vacunales aplicados contra enfermedades bacterianas, virales, cancerosas, o de otro origen. Desarrollo de formulaciones capaces de proteger o de elevar el espectro protector de vacunas ya existentes y extenderlo contra diferentes patógenos, empleando como blanco para la respuesta inmune, carbohidratos formados por unidades repetidas de (α 2-8) ácido neuramínico N-sustituidas. Se aislaron e identificaron péptidos como miméticos moleculares del polisacárido capsular de Neisseria meningitidis serogrupo B, formado por unidades repetidas de (α 2-8) ácido neuramínico N-acetilado. La inmunogenicidad de los péptidos se evaluó en biomodelos animales, demostrando su valor como antígenos inductores de anticuerpos capaces de reconocer específicamente a N. meningitidis del serogrupo B y de mostrar actividad bactericida contra la misma. Las formulaciones resultantes de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.
PCT/CU2006/000020 2005-12-29 2006-12-28 Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas WO2007073706A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002634067A CA2634067A1 (en) 2005-12-29 2006-12-28 Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations
EP06828471A EP1982994A2 (en) 2005-12-29 2006-12-28 Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations
MX2008008582A MX2008008582A (es) 2005-12-29 2006-12-28 Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas.
BRPI0620937-8A BRPI0620937A2 (pt) 2005-12-29 2006-12-28 peptìdeos de carbohidrato mimético e uso dos mesmos em formulação farmacêuticas
AU2006331226A AU2006331226A1 (en) 2005-12-29 2006-12-28 Carbohydrate-mimetic peptides and use thereof in pharmaceutical formulations
NO20083301A NO20083301L (no) 2005-12-29 2008-07-28 Karbohydrat-mimetiske peptider samt anvendelse derav i farmasoytiske sammensetninger

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20050283 2005-12-29
CU2005-0283 2005-12-29

Publications (2)

Publication Number Publication Date
WO2007073706A2 WO2007073706A2 (es) 2007-07-05
WO2007073706A3 true WO2007073706A3 (es) 2007-09-13

Family

ID=37946113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2006/000020 WO2007073706A2 (es) 2005-12-29 2006-12-28 Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas

Country Status (10)

Country Link
EP (1) EP1982994A2 (es)
KR (1) KR20080090477A (es)
CN (1) CN101389643A (es)
AR (1) AR058736A1 (es)
AU (1) AU2006331226A1 (es)
BR (1) BRPI0620937A2 (es)
CA (1) CA2634067A1 (es)
MX (1) MX2008008582A (es)
NO (1) NO20083301L (es)
WO (1) WO2007073706A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
WO1999010372A1 (en) * 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes
WO2002028888A2 (en) * 2000-10-03 2002-04-11 Glaxosmithkline Biologicals S.A. Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004334A1 (en) * 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
WO1998008874A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
US6642354B2 (en) * 1996-08-27 2003-11-04 Chiron Corporation Molecular mimetics of unique Neisseria meningitidis serogroup B epitopes
WO1999010372A1 (en) * 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes
WO2002028888A2 (en) * 2000-10-03 2002-04-11 Glaxosmithkline Biologicals S.A. Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENINATI C ET AL.: "Protective Immunization against Group B Meningococci Using Anti-Ideotypic Mimics of the Capsular Polysaccharide", THE JOURNAL OF IMMUNOLOGY, vol. 172, 2004, pages 2461 - 2468, XP002431249 *
MOE GR ET AL.: "Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 26, 1999, pages 209 - 226, XP002431251 *
PARK I ET AL.: "Peptide Mimotopes of Neisseria meningitidis Group B Capsular Polysaccharide", YONSEI MEDICAL JOURNAL, vol. 45, no. 4, 2004, pages 755 - 758, XP002431250 *

Also Published As

Publication number Publication date
EP1982994A2 (en) 2008-10-22
AR058736A1 (es) 2008-02-20
CA2634067A1 (en) 2007-07-05
MX2008008582A (es) 2008-09-26
WO2007073706A2 (es) 2007-07-05
NO20083301L (no) 2008-09-26
AU2006331226A1 (en) 2007-07-05
BRPI0620937A2 (pt) 2011-11-29
KR20080090477A (ko) 2008-10-08
CN101389643A (zh) 2009-03-18

Similar Documents

Publication Publication Date Title
TW200722101A (en) Novel composition
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
BRPI0607374B8 (pt) vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2008040362A3 (en) Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2008073891A3 (en) Salmonella vaccine in poultry
WO2009135199A3 (en) Vaccine compositions and methods
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2007073706A3 (es) Péptidos miméticos de carbohidratos y su empleo en formulaciones farmacéuticas
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2004084935A3 (en) Francisella strain for live vaccine
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies
WO2009077744A3 (en) Vaccines for brucellosis
WO2007120860A3 (en) Nanoemulsion vaccines
WO2009014382A3 (en) Cxcl11 adjuvant compositions and uses thereof
WO2007112702A3 (es) Composición farmacéutica que comprende la proteína nmb0938
WO2007087758A3 (es) Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas
WO2011114346A1 (en) Chitin and related compounds for use in treating bacterial and viral infections
WO2013066731A3 (en) Protective vaccine based on staphylococcus aureus sa2451 protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2634067

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008582

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006331226

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3755/CHENP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006331226

Country of ref document: AU

Date of ref document: 20061228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 570016

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2006331226

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087018521

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006828471

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680053451.5

Country of ref document: CN

ENP Entry into the national phase

Ref document number: PI0620937

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080630